

BOVIN et al
Appl. No. 10/593,829
November 24, 2008

RECEIVED
CENTRAL FAX CENTER
NOV 24 2008

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-167 (cancelled).

168 (new). A method of effecting change in the surface antigens expressed by a cell or a multi-cellular structure comprising the step of:

contacting a suspension of the cell or multi-cellular structure with a synthetic molecule construct of the structure F-S₁-S₂-L for a time and at a temperature sufficient to effect the change;

where:


F is a glycotope;

S₁ is a C₃₋₅-aminoalkyl selected from the group consisting of: 3-aminopropyl, 4-aminobutyl, or 5-aminopentyl;

S₂ is selected from the group consisting of: -CO(CH₂)₃CO-, -CO(CH₂)₄CO- (adipate) and -CO(CH₂)₅CO-; and

L is a lipid selected from the group consisting of diacyl- and dialkyl-glycerophospholipids.

169 (new). The method according to claim 168 where the construct includes the substructure:



where $n = 3$ to 5 , M is H or a monovalent cation selected from the group consisting of Na^+ , K^+ or NH_4^+ , and $*$ is other than H .

BOVIN et al
Appl. No. 10/593,829
November 24, 2008

170 (new). The method according to claim 168 where the cell or multi-cellular structure is of human or murine origin.

171 (new). The method according to claim 168 where the concentration of the construct in the suspension is in the range 0.1 to 10 mg/mL.

172 (new). The method according to 168 where the suspension of the cell or multi-cellular structure is contacted with the construct at a temperature in the range 2 to 37 °C.

173 (new). The method according to claim 172 where the suspension of the cell or multi-cellular structure is contacted with the construct at a temperature in the range 2 to 25 °C.

174 (new). The method according claim 173 where the suspension of the cell or multi-cellular structure is contacted with the construct at a temperature in the range 2 to 4 °C.

175 (new). The method according to claim 168 where F is selected from the group consisting of GalNAc α 1-3(Fuca1-2)Gal β ; Gal α 1-3Gal β ; Gal β ; Gal α 1-3(Fuca1-2)Gal β ; NeuAc α 2-3Gal β ; NeuAc α 2-6Gal β ; Fuca1-2Gal β ; Gal β 1-4GlcNAc β 1-6(Gal β 1-4GlcNAc β 1-3)Gal β ; Fuca1-2Gal β 1-4GlcNAc β 1-6(Fuca1-2Gal β 1-4GlcNAc β 1-3)Gal β ; Fuca1-2Gal β 1-4GlcNAc β 1-6(NeuAc α 2-3Gal β 1-4GlcNAc β 1-3)Gal β ; NeuAc α 2-3Gal β 1-4GlcNAc β 1-6(NeuAc α 2-3Gal β 1-4GlcNAc β 1-3)Gal β ; Gal α 1-4Gal β 1-4Glc; GalNAc β 1-3Gal α 1-4Gal β 1-4Glc; GalNAc α 1-3GalNAc β 1-3Gal α 1-4Gal β 1-4Glc; and GalNAc β 1-3GalNAc β 1-3Gal α 1-4Gal β 1-4Glc.


176 (new). The method according to claim 175 where F is selected from the group consisting of the oligosaccharides GalNAc α 1-3(Fuca1-2)Gal β and Gal α 1-3(Fuca1-2)Gal β .

BOVIN et al
Appl. No. 10/593,829
November 24, 2008

177 (new). The method according to claim 168 where S_1 is 3-aminopropyl.


178 (new). The method according to claim 168 where L is selected from the group consisting of 1,2-O-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE) and 1,2-O-distearyl-sn-glycero-3-phosphatidylethanolamine (DSPE).

179 (new). The method according to claim 168 where the construct is:



designated A_{tri} -sp-Ad-DOPE (I).


180 (new). The method according to claim 168 where the construct is:



designated A_{tri} -sp-Ad-DSPE (III).


BOVIN et al
Appl. No. 10/593,829
November 24, 2008

181 (new). The method according to claim 168 where the construct is:



designated B_{tri}-sp-Ad-DOPE (VI).


182 (new). The method according to claim 168 where the construct is:



designated H_{tri}-sp-Ad-DOPE (VII).


183 (new). The method according to claim 168 where the construct is:

BOVIN et al
 Appl. No. 10/593,829
 November 24, 2008




designated H_{dl}-sp-Ad-DOPE (VIII).

184 (new). The method according to claim 168 where the construct is:



designated Gal β -sp-Ad-DOPE (IX).


185 (new). The method according to claim 168 where the construct is:



designated Fuc α 1-2Gal β 1-3GlcNAc β 1-3Gal β 1-4GlcNAc-sp-Ad-DOPE (XII).

186 (new). The method according to claim 168 where the construct is:

BOVIN et al
Appl. No. 10/593,829
November 24, 2008



designated $Fuc\alpha 1-2Gal\beta 1-3(Fuc\alpha 1-4)GlcNAc-sp-Ad-DOPE$ (XIII).

187 (new). The method according to claim 168 where the cell or multi-cellular structure is a red blood cell.

188 (new). The method according to claim 187 where F is a ligand for a binding molecule where the presence of the binding molecule is diagnostic for a pathological condition.

189 (new). The method according to claim 188 where F is a ligand for an antibody (immunoglobulin).